Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Key Client Fiduciary Advisors LLC

Key Client Fiduciary Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 18.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,134 shares of the medical research company’s stock after purchasing an additional 173 shares during the quarter. Key Client Fiduciary Advisors LLC’s holdings in Amgen were worth $323,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in AMGN. GoalVest Advisory LLC increased its stake in Amgen by 215.9% in the 1st quarter. GoalVest Advisory LLC now owns 537 shares of the medical research company’s stock valued at $153,000 after buying an additional 367 shares during the period. Sovereign Financial Group Inc. boosted its holdings in shares of Amgen by 11.0% in the first quarter. Sovereign Financial Group Inc. now owns 1,451 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 144 shares in the last quarter. Elevated Capital Advisors LLC increased its stake in shares of Amgen by 8.0% during the first quarter. Elevated Capital Advisors LLC now owns 1,328 shares of the medical research company’s stock worth $378,000 after acquiring an additional 98 shares during the period. Constitution Capital LLC purchased a new position in Amgen during the first quarter worth about $218,000. Finally, Chemistry Wealth Management LLC lifted its position in Amgen by 20.0% in the first quarter. Chemistry Wealth Management LLC now owns 3,443 shares of the medical research company’s stock valued at $979,000 after purchasing an additional 573 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.69% of the company’s stock.

Amgen Trading Up 0.3 %

Shares of Amgen stock opened at $313.69 on Friday. The business’s fifty day moving average is $299.67 and its two-hundred day moving average is $291.67. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The firm has a market cap of $168.27 billion, a PE ratio of 44.81, a P/E/G ratio of 2.88 and a beta of 0.60. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same period in the prior year, the firm posted $3.98 EPS. The company’s revenue was up 22.0% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post 19.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AMGN. Morgan Stanley boosted their target price on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. BMO Capital Markets upped their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Raymond James assumed coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating for the company. Finally, StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.